Metagen Therapeutics utilizes microbiome science to develop fecal microbiota transplantation (FMT) therapies aimed at treating conditions such as ulcerative colitis and other microbiome-related diseases. By establishing a microbiome bank, the company enhances the accessibility and application of FMT, addressing the need for effective treatments in gastrointestinal health.
Funding
$14.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for ulcerative colitis and other microbiome-related diseases often lack effectiveness. Access to fecal microbiota transplantation (FMT) is limited, hindering its potential as a viable therapeutic option for patients suffering from these conditions.
Solution
Metagen Therapeutics is addressing these challenges by focusing on microbiome science to advance novel therapies, particularly FMT, for conditions like ulcerative colitis. The company is establishing a comprehensive microbiome bank to improve the accessibility and application of FMT. This involves collecting, processing, and storing a diverse range of microbial samples, ensuring a readily available resource for research and clinical use. By streamlining the FMT process and leveraging advanced microbiome analysis, Metagen Therapeutics aims to enhance treatment efficacy and broaden the availability of microbiome-based interventions. The company's approach includes both developing standardized FMT protocols and identifying specific microbial signatures associated with disease outcomes.
Target Audience
The primary target audience includes patients with ulcerative colitis and other microbiome-related diseases, as well as gastroenterologists and researchers seeking advanced treatment options and microbiome-based therapies.
Features
- Development of standardized fecal microbiota transplantation (FMT) protocols for consistent and reliable treatment.
- Establishment of a comprehensive microbiome bank to ensure a readily available resource for FMT and research.
- Advanced microbiome analysis to identify specific microbial signatures associated with disease outcomes.
- Focus on ulcerative colitis and other microbiome-related diseases.
- GMP-compliant processing and storage of fecal microbiota.